SPRB
Spruce Biosciences, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Spruce Biosciences (SPRB) Stock: Buy, Sell, or Hold?
$43.31
+0.42 (+0.98%)
â˛
5d:
-6.96%
30d:
+4.44%
90d:
-18.16%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (50%)
Quality Score
39/100
Position
FAIR
30-Day Fair Range
$41.62 â $46.55
Position: FAIR
Forward P/E & Valuation
9.9x
CHEAP
vs 11.5x historical avg
Wall Street Target
$147.44
+240.4% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$41.00 / $51.29
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: SPRB is fairly priced but lacks strong directional signals. At -5.1% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Get Alerted When SPRB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$70.80
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$43.96
1.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SPRB is currently trading at $43.31, which is considered fair relative to its 30-day fair value range of $41.62 to $46.55. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.9) compared to its historical average (11.5). Remarkably, the market is currently pricing in an annual earnings decline of 5.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, SPRB is in a downtrend. Immediate support is located at $41.00, while resistance sits at $51.29.
Market Sentiment: SPRB scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $147.44 (+240.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SPRB is in a downtrend. Immediate support is located at $41.00, while resistance sits at $51.29.
Market Sentiment: SPRB scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $147.44 (+240.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$41.62 -
$46.55
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
Trading Range & Key Levels
30-Day Trading Range
$41.62 -
$46.55
Current vs Trading Range
FAIR
Support Level
$41.00
Resistance Level
$51.29
Current Trend
Downtrend
Technical data as of
Nov 13, 2026
Quantitative Signal Breakdown
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 240.4% below Wall St target ($147.44)
- WARNING: Composite score 39/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
9.86
Wall Street Target
$147.44
(+240.4%)
Revenue Growth (YoY)
-75.9%
Valuation Discount vs History
-5.1% cheaper
PE vs Historical
9.9 vs 11.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.1%
(market-implied from PE analysis)
1-Year Target
$41.10
(-5%)
2-Year Target
$39.01
(-10%)
3-Year Target
$37.02
(-15%)
3-Yr Target (if PE normalizes)
(PE: 10â12)
$43.19
(0%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.9 to 11.5
Stabilization Target:
$50.53
(+16.7%)
PE Expansion Potential:
+16.7%
Share SPRB Analysis
Share this live SPRB analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (SPRB)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Oct 31, 2026
Daily AI digest
AI Retail Discussion Summary:
StockTwits message expresses bullish sentiment towards $SPRB, with one user referencing a similar situation from the past.
Key Retail Themes:
Historical Similarities
Trader Optimism
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 13, 2026 5:46 PM ET
Data refreshes hourly during market hours. Next update: 6:46 PM
Data refreshes hourly during market hours. Next update: 6:46 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SPRB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron PharmaceuticalâĻ |
BUY
28 analysts |
$978 | 41 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$296 | 37 SELL |
|
NAMS
NewAmsterdam Pharma CompâĻ |
STRONG BUY
16 analysts |
$50 | 55 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
17 analysts |
$34 | 52 HOLD |
|
ACAD
ACADIA Pharmaceuticals IâĻ |
STRONG BUY
20 analysts |
$31 | 46 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive SPRB Research Pages
